Drugs / 212Pb-DOTAM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07416552 | Jul 2026 → Feb 2034 expected | colorectal cancer | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 212Pb-DOTAM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07416552 ↗ |
| Modality | Other / unclassified | “212Pb-DOTAM as a therapeutic radioligand” NCT07416552 ↗ |